Week in Review: Xinbang Pharma Acquires Chinese Peptide Co. for $323 Million

Guizhou Xinbang Pharma acquired Chinese Peptide Company for $323 million and will invest another $106 million to increase CPC's peptide production capacity; FibroGen of San Francisco received a $15 million milestone from AstraZeneca for an anemia drug as part of an $800 million package for US-China rights to the drug; Provectus, a Tennessee clinical-stage biopharma, is up against an expiration deadline on a MOU with Sinopharm for China rights to a cancer treatment that it signed nine months ago; BGI of Shenzhen will be a reseller of Qiagen's bioinformatics program; China's Concord Medical, will develop cancer care programs with MD Anderson Cancer Center of Houston to use at its three China hospitals; Bayer AG said the CFDA approved two new anti-clotting indications for Xarelto; Shanghai Generon was granted FDA approval to begin a US Phase IIa clinical trial of its novel recombinant human interleukin; and PharmaEngine of Taiwan announced its licensing partners have applied for European marketing approval of a novel drug for metastatic pancreatic cancer. More details.... Stock Symbols: (SHE: 002390) (NSDQ: FGEN) (NYSE: AZN) (NYSE: PVCT) (NSDQ: QGEN) (NYSE: CCM) (XETRA: BAYN) (TWO:4162) Share this with colleagues: // //